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Abstract
Purpose The objective of this study was to explore the
pharmacology of GSK961081, a bi-functional bronchodi-
lator, in healthy volunteers.
Methods Two randomized, double-blind, placebo-con-
trolled studies were conducted. Following optimization of
the propranolol dosing regimen (study 1), we conducted a
five-period crossover study (study 2) in which subjects
received the following treatments: dry powder inhaler
(DPI) GSK961081 400 lg ? oral placebo, DPI
GSK961081 1,200 lg ? oral placebo, DPI GSK961081
400 lg ? oral propranolol 80 mg, DPI GSK961081 1,200
lg ? oral propranolol 80 mg and DPI and oral placebo.
GSK961081 (or inhaled placebo) was dosed at 0 h. Pro-
pranolol (or oral placebo) was dosed at -8, -2, 4, 10, and
16 h. The primary endpoint for both studies was bron-
chodilation, measured by specific airway conductance
(sGaw), which was assessed at 0, 1, 4, 7, 12, 22, and 24 h
in study 2. Tolerability and pharmacokinetics were sec-
ondary endpoints.
Results Studies 1 and 2 enrolled 18 and 23 subjects,
respectively. In study 2, bronchodilation was seen for 24 h
following GSK961081 400 and 1,200 lg. In the presence
of b2 blockade, GSK961081 1,200 lg demonstrated bron-
chodilation in the first 4 h after dosing (treatment differ-
ence from placebo at 1 h: 1.206; 90 % confidence interval
[CI] 1.126–1.292; and at 4 h: 1.124; 90 % CI 1.078–1.173)
but not at 7 h onwards. In the presence of b2 blockade,
GSK961081 400 lg demonstrated bronchodilation in the
first 1 h after dosing (treatment difference from placebo:
1.193; 90 % CI 1.117–1.274), but not at 4 h onwards.
Adverse events were reported for 21 (study 1) and 15
subjects (study 2); none were serious, and there were no
deaths.
Conclusion The duration of bronchodilation as a result of
receiving the muscarinic antagonist component alone was
shorter than that from the muscarinic antagonist b2 agonist
combination. Removing the b2 agonist component may
underestimate the contribution of the muscarinic antagonist
component to the bronchodilation of the combination.
Key Points
GSK961081 is a novel bi-functional molecule that
combines muscarinic antagonism (MA) and b2
agonism (BA) in a single molecule (MABA).
Bronchodilation following inhaled b2 agonist and
anti-muscarinic agents can be measured by specific
airway conductance (sGaw) in healthy volunteers.
We used this endpoint, in the presence and absence
of propranolol, to explore the pharmacology of
GSK961081.
The duration of bronchodilation following
GSK961081 from the muscarinic antagonist
component alone was shorter than that from the
MABA combination. However, removing the b2
component may underestimate the contribution of
the muscarinic antagonist component to the
bronchodilation of the combination.
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1 Introduction
Inhaled bronchodilators are the mainstay of the symp-
tomatic treatment of chronic obstructive pulmonary dis-
ease (COPD), and both long-acting b2 agonists (LABAs)
and long-acting muscarinic antagonists (LAMAs) are
frequently prescribed as maintenance therapy. A combi-
nation of these agents can provide greater efficacy for
patients who remain symptomatic on LABA or LAMA
monotherapy, and a number of studies have demonstrated
a superior bronchodilation effect with combined LABA
and LAMA compared with the individual agents alone
[1–6].
GSK961081 is a novel bi-functional molecule (or dual
pharmacophore) that combines muscarinic antagonism
(MA) and b2 agonism (BA) in a single molecule (MABA).
Pre-clinical data showed GSK961081 to be a potent func-
tional antagonist of muscarinic receptors, as well as a
potent, selective, and full agonist at the b2 adrenoceptor,
which produced significant and sustained bronchoprotec-
tion that was significantly greater than that with either of
the MA or BA components alone [7, 8]. Clinically,
GSK961081 at 400 and 1,200 lg once daily for 2 weeks
demonstrated sustained bronchodilation similar to a com-
bination of tiotropium 18 lg once daily plus salmeterol
50 lg twice daily but with a more rapid onset of action in
patients with moderate COPD [9]. Additionally, a dose of
400 lg once a day for 28 days resulted in a forced expi-
ratory volume in 1 s (FEV1) of 215 (139–291 at 95 %
confidence interval) mL greater than placebo in patients
with moderate and severe COPD [10]. It may be necessary
to understand the relative contribution of the b2 agonist
versus anti-muscarinic components of such a molecule in
humans. One way to do that is to block one of the com-
ponents. Bronchodilation following inhaled b2 agonist and
anti-muscarinic agents can be measured by specific airway
conductance (sGaw) in healthy volunteers [11–16]. Inhi-
bition of b2 agonist-mediated bronchodilation (as measured
by sGaw) in healthy volunteers by the non-selective b-
blocker propranolol has been reported previously [17–21].
However, published studies have generally looked at the
effect of a single dose of propranolol on a b2 agonist over a
relatively short (a few hours) period of time, have been
small, and have used various doses of propranolol and b2
agonist with various degrees of inhibition of bronchodila-
tion. Propranolol alone does not affect sGaw in healthy
volunteers [19]. However, there were no published data on
the effects of b blockade on sGaw following an inhaled
anti-muscarinic alone or the combination of inhaled b2
agonist and anti-muscarinic.
We therefore conducted and report two studies. Study 1
was conducted to confirm a dosing regimen of the b
antagonist propranolol, which prevents the increase in
sGaw to a b2 agonist over 24 h and had acceptable toler-
ability. It was also to confirm that the b antagonist pro-
pranolol did not prevent an increase in sGaw in response to
an anti-muscarinic and also to characterize the effect on
sGaw of a combination of an anti-muscarinic and b2 ago-
nist and the effect of propranolol on the combination.
Study 2 reports bronchodilation following the administra-
tion of GSK961081 in healthy volunteers in the presence
and absence of propranolol.
2 Methods
2.1 Subjects
Healthy adult male or female (study 1 only, as repro-
ductive toxicology had not been completed for
GSK961081 at the time of study) subjects aged
18–50 years inclusive with a body mass index (BMI)
within the range 19–29.9 kg/m2 were included. Subjects
were required to be non-smokers for at least 6 months
before the study, have no history of respiratory disease,
and have an FEV1 C80 % predicted and a FEV1/forced
vital capacity (FVC) ratio C0.7. Subjects were also
required to have an increase in sGaw of C15 % over pre-
dose baseline within 2 h of administration of salbutamol
600 lg by metered dose inhaler (MDI) at screening or in
the 3 months before screening and have an increase in
sGaw of C25 % over pre-dose baseline within 2 h fol-
lowing ipratropium bromide 40 lg at screening or in the
3 months before screening.
2.2 Study Design
Study 1 was a randomized, double-blind (with respect to
propranolol administration), open (with respect to bron-
chodilator administration), six-period crossover design
(GlaxoSmithKline [GSK], London, UK, study number:
MAB114954; www.clinicaltrials.gov: NCT00549120)
conducted at Parexel Clinical Research Unit (CRU), UK,
between 10 September 2007 and 22 October 2007. At study
period 1, subjects received propranolol 80 mg (five doses
at 6-h intervals) or placebo (five doses at 6-h intervals). At
study periods 2, 3, and 4, subjects received each of the
following three treatments in randomized order: propran-
olol 80 mg (five doses at 6-h intervals) ? MDI salbutamol
600 lg (four doses at 6-h intervals); placebo (five doses at
6-h intervals) ? MDI salbutamol 600 lg (four doses at 6-h
intervals); or propranolol 80 mg (five doses at 6-h inter-
vals) or placebo (five doses at 6-h intervals) (whichever
treatment was not taken in session 1). At study periods 5
and 6, subjects received propranolol 80 mg (two doses at
6-h intervals) ? MDI ipratropium 40 lg (two doses at 6-h
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intervals) ? MDI salbutamol 600 lg (one dose); and pla-
cebo (two doses at 6-h intervals) ? MDI ipratropium 40 lg
(two doses at 6-h intervals) ? MDI salbutamol 600 lg (one
dose). In study periods 1–4, propranolol was dosed at 0, 6,
12, 18, and 24 h and salbutamol was dosed at 2, 8, 14, and
20 h. In study periods 5 and 6, propranolol was dosed at 0
and 6 h, ipratropium at 2 and 8 h, and salbutamol at 8 h.
Subjects were randomized to treatment sequences in
accordance with the randomization schedule generated by
Clinical Pharmacology Statistics and Programming
(GlaxoSmithKline), using validated software (RandAll;
GlaxoSmithKline). The placebo tablets (white in color) did
not exactly match the propranolol tablets (pink in color),
and the blind was maintained by blindfolding the subjects
for propranolol or placebo administration.
Study 2 was a double-blind, placebo-controlled, five-
period crossover design (GSK study number: MAB110553;
www.clinicaltrials.gov: NCT00687700) conducted at Par-
exel CRU, UK, between 10 March 2008 and 27 May 2008.
Subjects received each of the five treatments in randomized
order: dry powder inhaler (DPI) GSK961081 400 lg ?
oral placebo, DPI GSK961081 1,200 lg ? oral placebo,
DPI GSK961081 400 lg ? oral propranolol 80 mg, DPI
GSK961081 1,200 lg ? oral propranolol 80 mg, and
inhaled DPI and oral placebo. GSK961081 (or inhaled
placebo) was dosed at 0 h. Propranolol (or oral placebo)
was dosed at -8, -2, 4, 10, and 16 h. Subjects were ran-
domized to treatment sequences in accordance with the
randomization schedule generated by Discovery Biomet-
rics, prior to the start of the study, using validated software
(RandAll). The placebo tablets (white in color) did not
exactly match the propranolol tablets (pink in color), and
tablets were over-encapsulated to maintain the blind.
Both studies included a washout of at least 7 days
between treatments, and subjects attended a follow-up visit
for safety approximately 1 week after completion of the
study periods. The study protocols and informed consent
were approved by the relevant ethics committees. Written
informed consent was obtained from each subject before
enrollment.
2.3 Pharmacodynamic Assessment (Primary Endpoint,
Both Studies)
Three sGaw measurements, using whole body plethys-
mography, were performed at each of the following time
points and the mean used in the data analysis. In study 1,
sGaw was measured at 0, 3, 6, 9, 15, and 26 h during study
periods 1–4 and at 0, 3, 6, and 9 h during study periods 5
and 6. In study 2, sGaw was measured at 0, 1, 4, 7, 12, 22,
and 24 h.
2.4 Pharmacokinetic Assessment (Secondary Endpoint,
Both Studies)
2.4.1 Propranolol
Blood (2 mL) for the determination of plasma propranolol
concentrations were collected pre-dose, 3, 4, 6, 9, 15, 26,
and 28 h post-dose in study 1, and -8, -2, 4, 10, 16, and
24 h post-GSK961081 dose in study 2. Plasma samples
were analyzed for propranolol using a validated analytical
method based on turbulent flow extraction, followed by
TFC-LC-MS/MS analysis. The lower limit of quantifica-
tion (LLQ) for propranolol was 1 ng/mL, using a 20-lL
aliquot of human plasma with a higher limit of quantifi-
cation (HLQ) of 250 ng/mL.
2.4.2 GSK961081 (Study 2 Only)
Blood samples (2 mL) for the determination of plasma
concentrations of GSK961081 (study 2) were collected
pre-GSK961081 dose and 0.5, 1, 2, and 4 h post-dose.
Human plasma samples were analyzed for GSK961081
using a validated analytical method based on protein pre-
cipitation, followed by HPLC/MS/MS analysis. The LLQ
for GSK961081 was 25 pg/mL using a 50-uL aliquot of
human plasma with a HLQ of 25,000 pg/mL. The com-
puter systems that were used on this study to acquire and
quantify data included Analyst Version 1.4.1 and SMS2000
versions 1.6 and 2.0.
Quality control (QC) samples for both the propranolol
and the GSK961081 assays were prepared at three dif-
ferent analyte concentrations and stored with study
samples, and were analyzed with each batch of samples
against separately prepared calibration standards. For the
analyses to be acceptable, no more than one-third of the
total QC results and no more than one-half of the results
from each concentration level were to deviate from the
nominal concentration by more than 15 %. The appli-
cable analytical runs met all predefined run acceptance
criteria.
2.4.3 Safety (Secondary Endpoint, Both Studies)
Safety laboratory tests were conducted at screening visit
and follow-up for both studies and also 32 h after each
inhaled dose for study 2. 12-lead electrocardiogram (ECG),
blood pressure, and heart rate were collected frequently
throughout both studies. Glucose and potassium were also
collected frequently during study 2. Adverse events (AEs)
were collected.
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2.5 Dose Rationale
2.5.1 GSK961081
Doses of 400 and 1,200 lg were selected as these were
studied in a 14-day efficacy study in patients with COPD;
these doses gave comparable efficacy [9].
2.5.2 Salbutamol
A dose of salbutamol 600 lg 6 hourly (four doses) was
selected to maintain b-agonist activity over the 24-h per-
iod. Whilst lower doses would give effective bronchodi-
lation [12], it was important to test the effectiveness of the
propranolol regimen at higher than effective bronchodilator
doses.
2.5.3 Ipratropium
Ipratropium 40 lg was selected as this dose has been
shown to have effective bronchodilation [13] in healthy
volunteers. It was also important to use a dose that was at
the lower end of the effective dose range.
2.5.4 Propranolol
For study 1, a dose of propranolol 80 mg 6 hourly (five
doses in periods 1–4 and two doses in periods 5 and 6) was
selected. Using published propranolol information on its
pharmacokinetics in humans [22] and its in vitro affinity
for the b2 receptor (pA2 = 9.4, competitive antagonist
[23]), various propranolol dosing scenarios were simulated
using Berkeley Madonna version 8.3.14 to determine a
dosing regimen to maintain plasma propranolol concen-
trations above the in vitro predicted 90 % effective con-
centration (EC90). The final propranolol dosing regimen
selection was based on clinical safety experience [24] and
the simulated scenarios, and allowed for the dosing interval
of propranolol to be increased from once every 6 h to once
every 8 h if tolerability issues arose.
For study 2, a dose of 80 mg propranolol 6 hourly (five
doses) was selected. The dose selection was based on the
results of study 1, where plasma propranolol concentrations
were above the in vitro predicted EC90 (*10.53 ng/mL) in
all but 2 % of samples, indicating that adequate propran-
olol levels were achieved (Fig. 1). In addition, a population
pharmacokinetic model was fitted to the study 1 propran-
olol data to evaluate how many propranolol doses to
administer prior to GSK91081 and to determine whether
four rather than five propranolol doses would be sufficient.
It was determined by simulation that administering two
propranolol doses prior to GSK961081 and three propran-
olol doses post GSK961081 would maintain the lower
bound of the model predicted plasma propranolol concen-
tration profile above the in vitro predicted EC90 over the
duration under investigation (Fig. 1). This was also deter-
mined by simulation for a propranolol dose of 80 mg, thus
enabling dose modification if tolerability issues arose.
2.6 Statistical Methods
2.6.1 Pharmacodynamics
In study 1, a total of 18 subjects were randomized, with the
aim that 16 subjects would complete the study with
evaluable data; 16 evaluable subjects was calculated to
provide approximately 90 % power to detect the non-
inferiority at 5 % significance level, assuming within- and
between-subject standard deviations of 0.124 and 0.146 for
sGaw, respectively. Serial sGaw data were analyzed using
mixed effects modeling, following a natural logarithmic
transformation. Non-inferiority tests were performed. The
upper limit of 90 % confidence interval (CI) of the treat-
ment ratio was compared with 1.15 to assess the non-
inferiority of propranolol ? salbutamol versus placebo.
The lower limit of CI of the treatment ratio was compared
with 0.87 to assess the non-inferiority of propranolol ?
ipratropium versus placebo ? ipratropium and propranolol
? salbutamol ? ipratropium versus placebo ? salbutamol
? ipratropium.
For study 2, a total of 23 subjects were randomized, with
the aim that 20 subjects would complete the study with
evaluable data. No formal sample size calculation was
conducted, as no formal hypothesis was to be tested; the
focus was on estimation. The primary endpoint, serial
sGaw, was analyzed, following a natural logarithmic
transformation, using a mixed effects model. The model
fitted treatment, time, period, and treatment by time as
fixed effects; subject-level baseline, period-level baseline,
Fig. 1 Observed propranolol concentrations and model prediction
(Study 1). EC90 90 % effective concentration
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and period-level baseline by time as continuous covariates;
and subject as a random effect. Comparisons were made
between GSK961081 ? propranolol and placebo treatment
groups with the two different GSK961081 doses and at
various time points. Point estimates and corresponding
90 % CIs were constructed for the estimated differences.
2.6.2 Pharmacokinetics
Propranolol: In study 1, plasma propranolol concentration-
time data were analyzed by non-compartmental methods
using WinNonlin 4.1 Software (Pharsight, Mountain View,
CA, USA) to determine, for the first propranolol dosing
interval, the area under the curve from time 0 to 6 h
(AUCs), peak concentration (Cmax), and time to reach peak
(tmax). In addition, for study 1, a one-compartment model
with oral absorption was fitted to the propranolol concen-
tration–time data for all dosing intervals using the software
NONMEM VI.
GSK961081: In study 2, plasma GSK961081 concen-
tration–time data were analyzed by non-compartmental
methods using WinNonlin 4.1 Software to determine the
AUC to last quantifiable concentration (AUCt), Cmax, tmax,
and time of last quantifiable concentration (tlast).
3 Results
3.1 Subject Disposition
Demographic and baseline characteristics are summarized
in Table 1. Eight male and ten female healthy volunteers,
mean age 29.6 years (range 21–46) and mean BMI
23.7 kg/m2 (range 19.6–28.9) were randomized and com-
pleted study 1. Study 2 enrolled 23 healthy male volun-
teers, mean age 32.0 years (range 20–49) and mean BMI
24.7 kg/m2 (range 20.3–29.9). A total of 21 subjects
completed the study; two subjects were withdrawn due to
protocol violations (one positive result for drugs of abuse,
one positive for cotinine).
3.2 Pharmacodynamic Results
In study 1, propranolol alone did not affect sGaw (Fig. 2a;
Table 2). Inhalation of salbutamol 600 lg resulted in an
expected increase in sGaw (Fig. 2a; Table 2). No signifi-
cant bronchodilation was observed at the last time point
after inhalation of salbutamol, probably because the final
sGaw measurement was taken too long after the last sal-
butamol dose. Propranolol prevented the increase in sGaw
in response to salbutamol 600 lg (Fig. 2a); sGaw follow-
ing propranolol ? salbutamol was non-inferior to placebo
(Table 2).
In study 1, propranolol did not prevent the sGaw
response to ipratropium 40 lg (Fig. 2b); sGaw following
propranolol ? ipratropium was non-inferior to placebo ?
ipratropium (Table 2). Addition of salbutamol 600 lg to
ipratropium 40 lg showed a small trend to increased sGaw
compared with when salbutamol 600 lg was added to
ipratropium 40 lg in the presence of propranolol (Fig. 2b:
9-h time point), but the comparison showed that salbutamol
? ipratropium ? propranolol was non-inferior to salbuta-
mol ? ipratropium (Table 2).
In study 2, bronchodilation was seen for 24 h following
a single dose of both 400 and 1,200 lg GSK961081
(Fig. 3). In the presence of effective b2 blockade,
GSK961081 1,200 lg demonstrated bronchodilation in the
first 4 h after dosing (treatment difference from placebo at
1 h: 1.206 [90 % CI 1.126–1.292] and 4 h: 1.124 [90 % CI
1.078–1.173]) but not at 7 h onwards (Table 3). In the
presence of effective b2 blockade, GSK961081 400 lg
demonstrated bronchodilation in the first 1 h after dosing
(treatment difference from placebo: 1.193 [90 % CI
1.117–1.274]), but not at 4 h onwards (Table 3).
3.3 Pharmacokinetic Results
3.3.1 Propranolol
In study 1, plasma propranolol concentrations were above
the in vitro predicted EC90 (*10.53 ng/mL) in all but 2 %
of samples. There was no apparent difference in exposure
to propranolol when administered alone or in combination
with either salbutamol or ipratropium and salbutamol
(Table 4). The propranolol population pharmacokinetic
model gave a reasonable fit to the observed data (Fig. 1)
and model predicted AUCs, Cmax, and tmax were compa-
rable to the non-compartmental analysis results (data not
shown).
In study 2, plasma propranolol concentrations were
above the in vitro predicted EC90 (*10.53 ng/mL) in all
but 0.87 % of samples, all of which were prior to
GSK961081 administration.
3.3.2 GSK961081
In study 2, plasma GSK961081 systemic exposure (Cmax
and AUC(0–t)) was increased by approximately 60 % in the
presence of propranolol (Table 5). In the absence of pro-
pranolol, systemic exposure to GSK961081 was in line
with systemic exposure previously achieved in healthy
volunteers at similar dose levels. Propranolol was not
administered in the absence of GSK961081 in this study;
however, comparable trough propranolol levels were
achieved in study 1 after the first dose of propranolol 80 mg
(data not shown).
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3.4 Safety Results
In study 1, a total of 15 subjects experienced AEs. The
most frequently reported AEs were headache (21 reports),
tremor (15), and dizziness (13 reports). All AEs were rated
as being mild or moderate in intensity, and no serious AEs
were reported. One subject (salbutamol ? placebo) missed
one dose of propranolol due to an increase in corrected QT
Table 1 Summary of baseline and demographic characteristics (studies 1 and 2)
Characteristics Study 1 (MAB104954) N = 18 Study 2 (MAB110553) N = 23
Age, years 29.6 (21–46) 32.0 (20–49)
Male 8 (44) 23 (100)
Ethnicity
Hispanic/Latino 1 (6) 2 (9)
Not Hispanic/Latino 17 (94) 21 (91)
Race
African American/African heritage 3 (17) 1 (4)
Asian–Central/South Asian heritage 2 (11) 2 (9)
Asian–East Asian heritage 0 (0) 1 (4)
Asian–Japanese heritage 1 (6) 0 (0)
Asian–South East Asian heritage 0 (0) 2 (9)
Native Hawaiian or other Pacific Islander 1 (6) 0 (0)
White–White Caucasian/European heritage 10 (56) 17 (74)
Mixed race 1 (6) 0 (0)
Height, cm 172.7 (161–191) 173.3 (157–193)
Weight, kg 70.8 (56.1–86.3) 74.23 (60–93)
BMI, kg/m2 23.67 (19.6–28.9) 24.70 (20.3–29.6)
Data are presented as mean (range) or n (%) unless otherwise indicated
BMI body-mass index
Table 2 Summary of statistical analysis of log-transformed specific airway resistance (1/KPa*s) data (study 1)
Treatment H N Adjusted geometric mean Treatment ratio
Estimate SE logs Estimate 90 % CI
PRO ? SAL (vs. PL) 3 18 0.824 0.0249 1.069 1.012–1.130
6 18 0.778 0.0311 0.966 0.900–1.037
9 18 0.841 0.0330 1.025 0.951–1.106
15 18 0.780 0.0355 1.043 0.961–1.131
26 18 0.762 0.0257 0.961 0.907–1.018
PL ? SAL (vs. PL) 3 18 0.965 0.0249 1.253 1.185–1.325
6 18 0.932 0.0311 1.157 1.078–1.243
9 18 1.045 0.0329 1.273 1.180–1.374
15 18 0.990 0.0354 1.322 1.218–1.435
26 18 0.808 0.0261 1.020 0.962–1.082
PRO only (vs. PL) 3 18 0.753 0.0270 0.978 0.925–1.034
6 18 0.772 0.0330 0.959 0.893–1.030
9 18 0.808 0.0347 0.984 0.912–1.062
15 18 0.748 0.0371 0.999 0.920–1.085
26 18 0.767 0.0278 0.968 0.913–1.027
PRO ? IPR (vs. PL ? IPR) 3 18 0.901 0.0278 0.973 0.934–1.014
PRO ? IPR ? SAL (vs. PL ? IPR ? SAL) 9 18 0.905 0.0316 0.926 0.876–0.978
CI confidence interval, H hour, IPR ipratropium, PL placebo, PRO propranolol, SAL salbutamol, SE standard error
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interval (QTc) of potential clinical concern to the investi-
gator. There were no clinically important findings in other
safety assessments.
In study 2, a total of 21 subjects experienced AEs. The
most frequently reported AEs were dysgeusia (24 reports),
dizziness (seven reports), and headache (six reports). All
AEs were rated as being mild or moderate in intensity, and
no serious AEs were reported. One subject (GSK961081
1,200 lg ? propranolol) had a PR interval of 224 at 6 h
after the first dose of propranolol and therefore did not have
further doses of propranolol. The efficacy data for this
subject were not included in the analysis for this treatment.
There were no clinically important findings in other safety
assessments. Potassium and glucose data were similar at all
time points (pre-dose, 1, 4, and 24 h) across all treatments,
including placebo.
Fig. 2 a sGaw following placebo alone, propranolol alone, salbutamol alone, and propranolol ? salbutamol (study 1). b sGaw following
propranolol ? ipratropium and propranolol ? ipratropium ? salbutamol (study 1). sGaw specific airway conductance
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4 Discussion
In study 1, inhalation of salbutamol 600 lg (? placebo)
resulted in the expected bronchodilation. At the final time
point for sGaw assessment, 6 h after the last dose of sal-
butamol, there was no increase in sGaw. This is because
the final sGaw measurement was taken too long after the
last salbutamol dose. Our data are consistent with pub-
lished data showing that sGaw 6 h after salbutamol is the
same as after placebo [14]. The propranolol regimen used
prevented the increase in sGaw in response to salbutamol
600 lg, but did not prevent the sGaw response to ipratro-
pium 40 lg. Therefore, we have demonstrated a propran-
olol dosing regimen that was effective in preventing
bronchodilation to a supra-therapeutic dose of b2 agonist,
but that did not prevent the bronchodilation to a low dose
of anti-muscarinic.
This is the first study where the effect of combined
salbutamol and ipratropium on sGaw has been explored in
healthy volunteers. Whilst there was a trend to an increase
in sGaw when salbutamol was added to ipratropium, this
assessment does not appear to be sensitive enough to detect
the benefit of the two mechanisms in healthy volunteers.
This is in contrast to this endpoint in COPD patients, where
a single dose of salmeterol 50 lg (? fluticasone propionate
500 lg) ? tiotropium 18 lg was significantly more
effective than tiotropium or salmeterol (? fluticasone)
alone in improving post-dose sGaw [25].
Fig. 3 Estimated treatment ratios (and 90 % CIs) sGaw versus
placebo (study 2). CI confidence interval, sGaw specific airway
conductance
Table 3 Summary of statistical analysis of log-transformed specific airway resistance (1/KPa*s) data (study 2)
Treatment H N Adjusted geometric mean Treatment ratio (vs. Placebo)
Estimate SE logs Estimate 90 % CI
081 400 lg ? PRO 1 23 1.176 0.0291 1.193 1.117–1.274
4 23 1.050 0.0195 1.025 0.985–1.067
7 23 1.044 0.0269 1.014 0.955–1.077
12 23 0.983 0.0223 1.010 0.963–1.059
22 23 0.923 0.0226 0.951 0.906–0.998
24 22 0.985 0.0239 0.998 0.948–1.051
081 1,200 lg ? PRO 1 22 1.189 0.0309 1.206 1.126–1.292
4 22 1.151 0.0207 1.124 1.078–1.173
7 22 1.049 0.0286 1.019 0.956–1.085
12 22 0.989 0.0236 1.016 0.966–1.068
22 22 0.927 0.0240 0.955 0.907–1.005
24 22 0.976 0.0249 0.989 0.938–1.044
081 400 lg only 1 23 1.154 0.0292 1.171 1.099–1.248
4 23 1.145 0.0196 1.118 1.075–1.162
7 23 1.110 0.0270 1.078 1.017–1.143
12 23 1.093 0.0224 1.123 1.072–1.176
22 23 1.050 0.227 1.081 1.031–1.133
24 23 1.092 0.0235 1.107 1.053–1.163
081 1,200 lg only 1 23 1.177 0.0292 1.194 1.120–1.273
4 23 1.190 0.0196 1.161 1.117–1.207
7 23 1.136 0.0270 1.104 1.041–1.170
12 23 1.112 0.0224 1.142 1.091–1.196
22 23 1.079 0.0227 1.111 1.060–1.165
24 23 1.110 0.0236 1.125 1.071–1.182
CI confidence interval, H hour, PRO propranolol, SE standard error, 081 GSK961081
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In study 2, bronchodilation was seen for 24 h following
a single dose of both 400 and 1,200 lg GSK961081. In the
presence of effective b2 blockade, GSK961081 1,200 lg
demonstrated bronchodilation in the first 4 h after dosing
but not at 7 h onwards, whilst GSK961081 400 lg dem-
onstrated bronchodilation in the first 1 h after dosing, but
not at 4 h onwards. Therefore, in this model, the MA alone
bronchodilation is of shorter duration than the bronchodi-
lation achieved with the MA/BA activity combined.
This assessment may underestimate the MA contribu-
tion to the MA/BA activity combined. Amplification of
bronchodilation achieved by one component by the other
component is believed to contribute to the benefit of
combined anti-muscarinic and b2 agonist [26]. Investiga-
tive studies have suggested that the enhanced MABA
activity compared with the single ligands may be due to
crosstalk between the engaged M3 and b2 receptors [27].
Crosstalk between the receptors could be reduced or
abolished by blocking the b receptor as has been done in
the reported clinical studies.
Therefore, removing the BA component completely
may underestimate the contribution of the MA component
to the bronchodilation of the combination by removing the
potential for amplification of one mechanism by the other.
In addition, the response in healthy volunteers may not be
the same as in COPD patients. In COPD patients, salbu-
tamol and ipratropium have been added at 1, 12, and 24 h
following single doses of GSK961081 400 and 1,200 lg
[28]. In that study, the additional bronchodilation following
salbutamol and ipratropium inhalation was similar, and this
indirect assessment may indicate that the activities of the
MA and BA components are of a similar magnitude. A
further limitation is that the study looked at single-dose
GSK961081 only; investigating the response after repeat
dosing would also be of interest.
In both studies, all dosing regimens were well tolerated.
There were no serious AEs, and all AEs reported were
consistent with the known effects of propranolol and sal-
butamol or the AEs previously reported with GSK961081
[9, 10, 28].
Pharmacokinetic modeling was used to inform pro-
pranolol dose selection for the two studies. The propranolol
dosing regimen (five doses of propranolol 80 mg at 6-h
intervals) was safe and well tolerated and shown to provide
plasma propranolol concentrations above the in vitro pre-
dicted EC90 throughout the treatment session. This pro-
pranolol dosing regimen was effective at preventing the
increase in sGaw in response to salbutamol 600 lg.
However, it is possible that propranolol did not completely
block the effects of the BA component of the MABA, and
some of the bronchodilation seen following MABA in the
presence of propranolol is due to residual BA effect. There
was no apparent difference in exposure to propranolol
when administered alone or in combination with either
salbutamol or ipratropium and salbutamol. GSK961081
systemic exposure (Cmax and AUCt) was increased by
approximately 60 % in the presence of propranolol. In vitro
data suggest that the difference is unlikely to be a result of





PRO only 18/18 55.12 (38.84–78.21) 201.5 (142.2–285.6) 3.05 (3.00–4.00)
PRO ? SAL 18/18 63.97 (45.96–89.04) 234.0 (166.3–329.2) 3.05 (3.02–5.90)
PRO ? IPR ? SAL 18/18 69.78 (52.04–93.55) 258.6 (191.7–348.8) 3.07 (3.00–4.00)
AUCs area under the concentration time curve from time 0 to 6 h, CI confidence interval, Cmax maximum observed plasma concentration, IPR
ipratropium, PRO propranolol, SAL salbutamol, tmax time to maximum observed concentration
a Geometric mean (95 % CI)
b Median (range)






081 400 lg ? PRO 23/23 165,236 (147,292–185,367) 204,816 (178,161–235,459) 0.50 (0.43–1.12) 2.02 (0.98–3.88)
081 1,200 lg ? PRO 23/23 528,172 (464,459–600,624) 870,949 (768,076–987,602) 0.98 (0.47–1.08) 3.83 (2.02–3.88)
081 400 lg only 23/23 101,052 (89,546–114,036) 121,249 (97,867–150,218) 0.95 (0.45–1.12) 2.02 (0.97–3.98)
081 1,200 lg only 23/23 307,291 (264,677–356,765) 585,333 (502,799–681,416) 0.98 (0.48–1.07) 3.85 (2.02–3.90)
AUC area under the concentration–time curve, CI confidence interval, Cmax maximum observed plasma concentration, PRO propranolol, tmax
time to maximum observed concentration, 081 GSK961081
a Geometric mean (95 % CI)
b Median (range)
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metabolic interaction or plasma protein-binding displace-
ment. Propranolol is a cytochrome P450 (CYP)1A2,
CYP2D6, and CYP2C19 substrate with a minor route
(*15 %) via direct glucuronidation; whereas that of
GSK961081 appears to be by direct glucuronidation and a
CYP3A4 substrate. A postulated reason for the difference
is that GSK961081 apparent clearance is decreased as a
result of a decrease in liver blood flow in the presence of
propranolol (b2 adrenoceptor mediated).
In conclusion, in this healthy volunteer model, the
duration of bronchodilation from the MA component alone
was of shorter duration than that achieved from the MA/
BA combination.
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